(Trial in progress) A real-life prospective, observational, post-authorisation safety study in adult breast cancer patients treated with neratinib in extended adjuvant in Europe: the NERLYFE study

Saved in:
Bibliographic Details
Published in:Breast (Edinburgh) 2021-04, Vol.56, p.S20
Main Authors: Valenti, R., Plantet, C., Tadmouri, A.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue
container_start_page S20
container_title Breast (Edinburgh)
container_volume 56
creator Valenti, R.
Plantet, C.
Tadmouri, A.
description
doi_str_mv 10.1016/S0960-9776(21)00095-3
format article
fullrecord <record><control><sourceid>doaj_cross</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_c1b7c6d4d5b64ea885741a97acd35361</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_c1b7c6d4d5b64ea885741a97acd35361</doaj_id><sourcerecordid>oai_doaj_org_article_c1b7c6d4d5b64ea885741a97acd35361</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1593-310e85f1bdc82d0f5eede93ccf43843d1f4f49496b32821a6ce89727c3e48b6a3</originalsourceid><addsrcrecordid>eNo9kcFq3DAQhkVpoNukj1DQMYG4lSxblnoLYdMGlhaS9NCTGEvjrBbXMpK86b5fH6z2bslJ8Omfb2B-Qj5y9okzLj8_Mi1ZoZtGXpb8ijGm60K8IStei7IQTLG3ZPUaeUfep7RbQkKqFfl7-RQ99NQPdIzhOWJKV_SGRoS-6H2HC00j2uz3eE1DmzDuIfswQH9Nx5ByAVPehujTkdIEHeYDTXlyh0UKbuozbWdfytTCYDHScY7ikBPNM87o6IvPWzpgnPng22UM_2Qc3PwFbjftYcgLXE8xjPiF5i3S7-uHza-79WnRBTnroE_44f97Tn7erZ9uvxWbH1_vb282heW1FoXgDFXd8dZZVTrW1YgOtbC2q4SqhONd1VW60rIVpSo5SItKN2VjBVaqlSDOyf3J6wLszBj9b4gHE8CbIwjx2UDM3vZoLG8bK13l6lZWCErVTcVBN2CdqIXks6s-uex84BSxe_VxZpZazbFWs3RmSm6OtRoh_gHgVpo8</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>(Trial in progress) A real-life prospective, observational, post-authorisation safety study in adult breast cancer patients treated with neratinib in extended adjuvant in Europe: the NERLYFE study</title><source>Elsevier</source><source>PubMed Central</source><creator>Valenti, R. ; Plantet, C. ; Tadmouri, A.</creator><creatorcontrib>Valenti, R. ; Plantet, C. ; Tadmouri, A.</creatorcontrib><identifier>ISSN: 0960-9776</identifier><identifier>EISSN: 1532-3080</identifier><identifier>DOI: 10.1016/S0960-9776(21)00095-3</identifier><language>eng</language><publisher>Elsevier</publisher><ispartof>Breast (Edinburgh), 2021-04, Vol.56, p.S20</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Valenti, R.</creatorcontrib><creatorcontrib>Plantet, C.</creatorcontrib><creatorcontrib>Tadmouri, A.</creatorcontrib><title>(Trial in progress) A real-life prospective, observational, post-authorisation safety study in adult breast cancer patients treated with neratinib in extended adjuvant in Europe: the NERLYFE study</title><title>Breast (Edinburgh)</title><issn>0960-9776</issn><issn>1532-3080</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNo9kcFq3DAQhkVpoNukj1DQMYG4lSxblnoLYdMGlhaS9NCTGEvjrBbXMpK86b5fH6z2bslJ8Omfb2B-Qj5y9okzLj8_Mi1ZoZtGXpb8ijGm60K8IStei7IQTLG3ZPUaeUfep7RbQkKqFfl7-RQ99NQPdIzhOWJKV_SGRoS-6H2HC00j2uz3eE1DmzDuIfswQH9Nx5ByAVPehujTkdIEHeYDTXlyh0UKbuozbWdfytTCYDHScY7ikBPNM87o6IvPWzpgnPng22UM_2Qc3PwFbjftYcgLXE8xjPiF5i3S7-uHza-79WnRBTnroE_44f97Tn7erZ9uvxWbH1_vb282heW1FoXgDFXd8dZZVTrW1YgOtbC2q4SqhONd1VW60rIVpSo5SItKN2VjBVaqlSDOyf3J6wLszBj9b4gHE8CbIwjx2UDM3vZoLG8bK13l6lZWCErVTcVBN2CdqIXks6s-uex84BSxe_VxZpZazbFWs3RmSm6OtRoh_gHgVpo8</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Valenti, R.</creator><creator>Plantet, C.</creator><creator>Tadmouri, A.</creator><general>Elsevier</general><scope>AAYXX</scope><scope>CITATION</scope><scope>DOA</scope></search><sort><creationdate>202104</creationdate><title>(Trial in progress) A real-life prospective, observational, post-authorisation safety study in adult breast cancer patients treated with neratinib in extended adjuvant in Europe: the NERLYFE study</title><author>Valenti, R. ; Plantet, C. ; Tadmouri, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1593-310e85f1bdc82d0f5eede93ccf43843d1f4f49496b32821a6ce89727c3e48b6a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Valenti, R.</creatorcontrib><creatorcontrib>Plantet, C.</creatorcontrib><creatorcontrib>Tadmouri, A.</creatorcontrib><collection>CrossRef</collection><collection>Directory of Open Access Journals</collection><jtitle>Breast (Edinburgh)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Valenti, R.</au><au>Plantet, C.</au><au>Tadmouri, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>(Trial in progress) A real-life prospective, observational, post-authorisation safety study in adult breast cancer patients treated with neratinib in extended adjuvant in Europe: the NERLYFE study</atitle><jtitle>Breast (Edinburgh)</jtitle><date>2021-04</date><risdate>2021</risdate><volume>56</volume><spage>S20</spage><pages>S20-</pages><issn>0960-9776</issn><eissn>1532-3080</eissn><pub>Elsevier</pub><doi>10.1016/S0960-9776(21)00095-3</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0960-9776
ispartof Breast (Edinburgh), 2021-04, Vol.56, p.S20
issn 0960-9776
1532-3080
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_c1b7c6d4d5b64ea885741a97acd35361
source Elsevier; PubMed Central
title (Trial in progress) A real-life prospective, observational, post-authorisation safety study in adult breast cancer patients treated with neratinib in extended adjuvant in Europe: the NERLYFE study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T23%3A47%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-doaj_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=(Trial%20in%20progress)%20A%20real-life%20prospective,%20observational,%20post-authorisation%20safety%20study%20in%20adult%20breast%20cancer%20patients%20treated%20with%20neratinib%20in%20extended%20adjuvant%20in%20Europe:%20the%20NERLYFE%20study&rft.jtitle=Breast%20(Edinburgh)&rft.au=Valenti,%20R.&rft.date=2021-04&rft.volume=56&rft.spage=S20&rft.pages=S20-&rft.issn=0960-9776&rft.eissn=1532-3080&rft_id=info:doi/10.1016/S0960-9776(21)00095-3&rft_dat=%3Cdoaj_cross%3Eoai_doaj_org_article_c1b7c6d4d5b64ea885741a97acd35361%3C/doaj_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1593-310e85f1bdc82d0f5eede93ccf43843d1f4f49496b32821a6ce89727c3e48b6a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true